New drug rocbrutinib takes on pirtobrutinib in blood cancer showdown
NCT ID NCT07342478
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 3 times
Summary
This study tests a new drug, rocbrutinib, against another drug, pirtobrutinib, in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned or stopped responding to treatment. All participants have already tried a type of BTK inhibitor. The goal is to see which drug works better at controlling the cancer for longer. About 306 adults will take one pill daily until their disease worsens or side effects become too much.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medical Oncology Associates - Spokane
RECRUITINGSpokane, Washington, 99208, United States
-
OSU Comprehensive Cancer Center
NOT_YET_RECRUITINGColumbus, Ohio, 43210, United States
-
Optum Medical Group (Rhodes) P.C.
RECRUITINGLas Vegas, Nevada, 89102, United States
-
Orchard Healthcare Research
RECRUITINGSkokie, Illinois, 60077, United States
-
The Center for Cancer and Blood Disorders-Bethesda
RECRUITINGBethesda, Maryland, 20817, United States
-
UPMC Hillman Cancer Center
NOT_YET_RECRUITINGPittsburgh, Pennsylvania, 15213, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Zinc-Based compound fight cancer?
- Can a new drug combo outsmart resistant lymphomas?
- Can a Chemo-Free pill combo outsmart leukemia at first diagnosis?
- Could bone marrow from deceased donors cure blood cancers?
- Engineered immune cells get a boost: new combo therapy targets Hard-to-Treat blood cancers
- Two-Drug sequence aims to clear CLL cells and let patients stop treatment